MeiraGTx Stock Drops After $100M Share Offering and Bota-Vec Buy from Johnson & Johnson
MeiraGTx stock fell after $100M share sale to raise cash. Money will fund gene therapy drugs and future launches.
/ 13 items
#JNJ↓
Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
J&J Eyes Big Sale of Its Orthopedics Business DePuy Synthes
Johnson & Johnson is exploring a potential $20B+ sale of its orthopedics unit DePuy Synthes instead of spinning it off, drawing interest from private equity firms in a major healthcare deal.
Johnson & Johnson Q4 Earnings Beat, But Stock Falls on Stelara
Johnson & Johnson reports Q4 earnings of $2.46/share, beating estimates with 9.1% sales growth to $24.6B, but stock falls 3% on Stelara patent loss concerns.
J&J's MajesTEC-3 Data Creates Competitive Landscape in Multiple Myeloma Treatment
Johnson & Johnson's (JNJ) Tecvayli-Darzalex combination shows strong Phase 3 results in multiple myeloma, creating competitive pressure for CAR-T therapies like Carvykti (LEGN) while offering new treatment options.
Bayer's Stroke Prevention Drug Shows Promise, Reviving Hope for New Blood Clot Treatment Class
Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.